Latest News on PFE

Financial News Based On Company


Advertisement
Advertisement

What Drives Our Scientists: Dafydd Owen

https://www.pfizer.com/news/articles/what_drives_our_scientists_dafydd_owen
Dafydd Owen, Senior Director, Medicinal Chemistry at Pfizer, finds deep purpose in his work, driven by the privilege of inventing molecules that can become life-saving medicines. Early in his career, he was inspired by a chemist whose invention benefited his own grandmother, solidifying his desire to contribute to medicine development for others. Owen emphasizes the creativity and profound responsibility involved in being a chemist who physically creates new molecules.

4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover

https://247wallst.com/investing/2026/11/20/4-dividend-stocks-wall-street-gave-up-on-with-balance-sheets-built-to-recover/
This article highlights four dividend stocks—Pfizer, Bristol-Myers Squibb, T. Rowe Price, and United Parcel Service—that Wall Street has largely dismissed despite their strong balance sheets and ability to maintain dividend payouts. The author argues that despite market pessimism and analyst downgrades, these companies are well-positioned for recovery due to manageable debt, steady cash flow, and growing core businesses. Each company's financial health, dividend coverage, and unique strengths are detailed, emphasizing why the market's negative outlook may be overdone.

4 Yield Traps Paying Over 6% That Retirees Should Watch Out For

https://247wallst.com/investing/2026/11/20/4-yield-traps-paying-over-6-that-retirees-should-watch-out-for/
This article warns retirees about four high-yield stocks—AGNC Investment (AGNC), Ares Capital (ARCC), Verizon (VZ), and Pfizer (PFE)—that may be "yield traps" due to underlying financial weaknesses. While offering attractive dividends, these companies face challenges such as shrinking book value, earnings not covering payouts, heavy debt, and patent expirations, all of which could lead to dividend cuts and principal losses for investors. The author provides a checklist for retirees to identify potential yield traps, emphasizing the importance of examining financial coverage, leverage, and dividend history.

Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill

https://247wallst.com/investing/2026/11/20/pfizer-yields-6-25-these-3-dividend-stocks-pay-more-than-a-1-year-treasury-bill/
This article highlights three dividend stocks—Pfizer (PFE), British American Tobacco (BTI), and Enbridge (ENB)—that offer higher yields than a one-year Treasury bill's 4.59%, providing diversification across healthcare, tobacco, and energy. Each company's dividend is backed by strong cash flow, debt targets, and a consistent payment history, making them attractive for long-term income-focused investors willing to accept more risk than T-bills. The article details the dividend safety, bull case, and risks for each company, emphasizing their ability to maintain and grow payouts despite industry challenges.

AbbVie bets on dual-target cancer therapies in Disco research deal

https://www.emjreviews.com/emj-gold/news/abbvie-bets-on-dual-target-cancer-therapies-in-disco-research-deal/
AbbVie has partnered with Disco Pharmaceuticals to discover and develop new dual-target cancer therapies for solid tumours, paying $40 million upfront with potential payments of up to $2.5 billion plus royalties. This collaboration focuses on an 'AND-gating' approach, where experimental therapies require two specific target proteins to be present together on cancer cells, aiming to improve specificity and reduce damage to healthy tissue. The deal strengthens AbbVie's bispecific cancer portfolio, building on a previous agreement with RemeGen, and emphasizes early-stage discovery investment.
Advertisement

Sidley Represents Starna Therapeutics in Licensing Agreement With Pfizer Valued at Up to US$2.6 Billion

https://legaldesire.com/sidley-represents-starna-therapeutics-in-licensing-agreement-with-pfizer-valued-at-up-to-us2-6-billion/
Sidley represented Starna Therapeutics in an exclusive licensing agreement with Pfizer Inc. valued at up to approximately US$2.6 billion, including a US$330 million upfront payment and potential milestone payments. Under the agreement, Pfizer gains exclusive rights to develop, manufacture, and commercialize three of Starna’s investigational in vivo chimeric antigen receptor T-cell (CAR-T) programs outside Greater China, and also obtains rights to use Starna’s proprietary technology in inflammation, immunology, and oncology. The Sidley team was led by Lila Hope and Jennifer Raab.

Johnson & Johnson’s $3.05 Billion Acquisition Delivers Early Returns as JNJ-6143 Shows Encouraging Early Efficacy

https://nai500.com/blog/2026/11/johnson-johnsons-3-05-billion-acquisition-delivers-early-returns-as-jnj-6143-shows-encouraging-early-efficacy/
Johnson & Johnson's $3.05 billion acquisition of Halda Therapeutics is showing early success as the core asset, JNJ-6143, achieved a 75% overall response rate in a Phase 1 prostate cancer trial. This promising early-stage data validates the acquisition and highlights Johnson & Johnson's strong R&D capabilities. Combined with new drug launches, a focus on pharmaceuticals and medical devices, and a 64-year streak of dividend increases, the company demonstrates strong innovation and shareholder return potential.

MRNA - Moderna Will Revolutionize Cancer Vaccines With Intismeran and Merck. But the market has already priced in a lot of success

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/dzy2lq41-moderna-will-revolutionize-cancer-vaccines-with-intismeran-and-merck-but-the-market-has-already-priced-in-a-lot-of-success
Moderna is transitioning from a COVID-vaccine company to a cancer-vaccine company, with its intismeran cancer vaccine (developed with Merck) showing promise, particularly in melanoma. While this new therapy offers significant market potential, the stock's substantial increase from $24 to $203 suggests that much of this success is already factored into its current price. Risks include regulatory hurdles, the full efficacy data not yet being released for Phase 3 trials, competition from BioNTech, and ongoing cash burn.

FDA Approval for Sanofi Drug Marks an Important First in Rare Disease

https://medcitynews.com/2026/11/sanofi-gaucher-disease-type3-venglustat-infilbray-fda-approval-gd3-san/
The FDA has approved Sanofi's Infilbray, a brain-penetrating small molecule, as the first therapy for the neurological symptoms of Gaucher disease type 3. This regulatory decision addresses the cognitive and movement problems caused by the rare inherited enzyme deficiency in adults and children weighing at least 15 kg. The approval is a significant milestone, providing a much-needed treatment for a devastating disorder whose neurological manifestations were previously untreatable.

Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer

https://www.pfizer.com/news/articles/learning_at_the_rate_of_evidence_how_ai_is_reshaping_r_d_at_pfizer
Pfizer is transforming its R&D operations by integrating AI across the entire drug development process, from discovery to pharmacovigilance. The ambitious goal is to halve the time from idea to first-in-human trials and then halve the time to approval by leveraging petabytes of proprietary data and AI models like FLOWR for molecule design and GENESIS for safety monitoring. This initiative aims to accelerate decision-making, enhance scientific judgment, and ultimately deliver breakthroughs to patients faster, all while maintaining rigorous trust, privacy, and regulatory standards.
Advertisement

Thomas L. Harrison, co-founder of Harrison & Star and architect of Omnicom's healthcare empire, has died

https://www.mmm-online.com/news/thomas-l-harrison-obituary-harrison-and-star-omnicom-healthcare/
Thomas L. Harrison, co-founder of Harrison & Star and a key figure in building Omnicom's healthcare marketing division, has passed away. Harrison, who was inducted into the Medical Advertising Hall of Fame in 2020, began his career as a cancer researcher before revolutionizing pharmaceutical sales and advertising with a science-first approach. He was known for his entrepreneurial spirit, his ability to mentor, and transforming Omnicom's Diversified Agency Services into a multi-billion dollar operation.

PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies

https://www.tradingview.com/news/zacks:1561f48db094b:0-pfe-inks-2-6b-licensing-deal-with-chinese-biotech-for-car-t-therapies/
Pfizer (PFE) has signed a $2.6 billion exclusive licensing deal with China's Starna Therapeutics for three investigational CAR-T programs targeting autoimmune diseases. This deal gives Pfizer rights outside Greater China to develop, manufacture, and commercialize these preclinical in vivo CAR-T therapies, with an upfront payment of $330 million and up to $2.3 billion in milestone payments. This move aligns with Pfizer's strategy to explore next-generation CAR-T therapies that modify T cells directly inside the patient's body, reducing complexities and costs associated with traditional CAR-T treatments.

Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?

https://www.tradingview.com/news/zacks:78d07d93f094b:0-moderna-can-the-vaccine-business-fund-its-next-phase-of-growth/
Moderna reported strong Q3 2026 results and raised its full-year revenue guidance, but concerns emerged after its Analyst Day regarding future spending commitments, particularly in oncology, without clear corresponding multi-year revenue projections. The company aims to diversify beyond COVID-19 vaccines by expanding its respiratory and oncology pipelines, despite facing stiff competition. Moderna's stock has significantly outperformed the industry year-to-date, though it trades at a premium valuation.

AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics

https://finance.yahoo.com/news/abbvie-disco-ink-2-5bn-153340392.html
AbbVie has partnered with German biotech Disco Pharmaceuticals in a deal potentially worth up to $2.5 billion, focusing on developing bispecific cancer therapies for solid tumors. AbbVie will pay $40 million upfront, with additional milestone payments and royalties, to leverage Disco's DISCOtech platform for designing selective bispecifics like AND-gated antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). This collaboration aims to address unmet needs in solid tumor indications by developing therapies with a wider therapeutic window and reduced off-tumor toxicity.

As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments

https://www.cnbc.com/2026/11/19/as-pompe-drug-shortage-drags-on-patients-struggle-to-get-treatments.html
A shortage of Sanofi's Pompe disease drugs, Lumizyme and Nexviazyme, has continued for over three months due to manufacturing issues at its Ireland facility, leaving some patients unable to receive critical bi-weekly infusions. Patients fear that these interruptions could lead to irreversible health declines, with one patient likening the experience to a severe flu. The FDA has cited Sanofi for manufacturing violations unrelated to the Pompe drugs, which the company says has contributed to the supply disruption.
Advertisement

Valion Bio names former Army official and biotech CEO as advisor

https://www.streetinsider.com/Corporate+News/Valion+Bio+names+former+Army+official+and+biotech+CEO+as+advisor/27373151.html
Valion Bio, Inc. has appointed Armand Balboni, JD, MD, PhD, as an advisor to lead its scientific strategy and medical countermeasure development, particularly for its lead candidate, Entolimod. Dr. Balboni's extensive background includes serving as CEO of Appili Therapeutics Inc. and 24 years of military service with the U.S. Army, where he oversaw FDA-regulated clinical trials. His expertise will be crucial in advancing Entolimod, which has Fast Track and Orphan Drug designations, through government and strategic partnerships.

GE HealthCare’s manganese contrast agent advances to phase 3

https://www.investing.com/news/company-news/ge-healthcares-manganese-contrast-agent-advances-to-phase-3-93CH-5038908
GE HealthCare announced that its investigational manganese-based MRI contrast agent, mangaciclanol, met the primary endpoint in Phase 2 of the LUMINA clinical trial and will now advance to Phase 3. The Phase 2 study demonstrated similar diagnostic preference to a gadolinium-based agent and was well-tolerated. This new agent offers a potential alternative to gadolinium, which is primarily sourced from China, while manganese is more readily available globally.

Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies

https://www.pharmaceutical-technology.com/news/pfizer-inks-2-6bn-autoimmune-deal-with-chinas-starna-for-car-t-therapies/
Pfizer has signed a multi-billion-dollar licensing agreement with China's Starna Therapeutics for ex-China rights to three pre-IND in vivo CAR-T programmes targeting autoimmune diseases. The deal includes an upfront payment of $330m to Starna, with potential for an additional $2.3bn in development and commercial milestones, plus royalties. This move aligns with a broader industry trend towards in vivo CAR-T therapies, which are seen as more attractive due to reduced manufacturing complexities compared to ex vivo approaches.

Corporate America demands a stronger voice on AI

https://www.axios.com/2026/11/19/jpmorgan-gm-pfizer-ai-regulation-frontier
Seven major corporations, including JPMorgan Chase, General Motors, and Pfizer, have formed America's AI Deployer Council to advocate for a greater say in AI policy and regulation. The group believes that businesses deploying AI in everyday operations have been excluded from crucial safety discussions, even though they bear the responsibility for managing associated risks. They also aim to highlight the benefits of AI to counter public skepticism.

Adagene doses first patient in phase 1 trial of ADG138

https://ca.investing.com/news/stock-market-news/adagene-doses-first-patient-in-phase-1-trial-of-adg138-93CH-4969381
Adagene Inc. (NASDAQ:ADAG) has announced that the first patient has been dosed in a phase 1 study for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The open-label study will assess the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors, with dose escalation starting at 2 mg. Preclinical data for ADG138 showed reduced cytokine release, a longer apparent half-life, and tumor regression in various HER2 tumor models.
Advertisement

RCS - Hutchmed China Ltd - China NMPA Approval of SYVIK

https://www.tradingview.com/news/reuters.com,2026-11-19:newsml_RSS8664Da:0-rcs-hutchmed-china-ltd-china-nmpa-approval-of-syvik/
HUTCHMED (China) Limited announced that China's NMPA has simultaneously approved two New Drug Applications for SYVIK® (sovleplenib) for the treatment of adult patients with chronic primary Immune Thrombocytopenia (ITP) and Warm Antibody Autoimmune Hemolytic Anemia (wAIHA). SYVIK® is the first novel Syk inhibitor approved in China, marking HUTCHMED's expansion into immunology beyond oncology. The approvals are supported by positive Phase III ESLIM-01 trial data for ITP and Phase II/III ESLIM-02 trial data for wAIHA, demonstrating significant efficacy and a tolerable safety profile.

Insmed shares jump more than 18% on report Sanofi is weighing acquisition

https://www.investing.com/news/stock-market-news/insmed-shares-jump-more-than-6-on-report-sanofi-is-weighing-acquisition-5039411
Insmed shares surged over 18% after Bloomberg reported that Sanofi is considering acquiring the U.S. drugmaker. Sanofi is reportedly consulting advisors regarding a potential transaction, which could be one of the largest biopharmaceutical acquisitions in recent years. While discussions are ongoing, there is no guarantee a deal will be reached, and other bidders may emerge.

TheyDo Shows How FedEx, Pfizer and Kimberly-Clark Turn Insight Into Results

https://www.dispatch.com/press-release/story/269999/theydo-shows-how-fedex-pfizer-and-kimberly-clark-turn-insight-into-results/
The article highlights how companies like FedEx, Pfizer, and Kimberly-Clark are leveraging customer intelligence to drive significant business improvements. Through examples shared at TheyDo's Beyond the Map 2026 event, it demonstrates how turning customer evidence into product decisions faster, assigning ownership of customer experience to business owners, and proving early outcomes can lead to reduced operating costs, accelerated product development, and enhanced customer retention. These case studies underscore the importance of evidence-based decision-making for 2027 strategy.

TheyDo Shows How FedEx, Pfizer and Kimberly-Clark Turn Insight Into Results

https://www.courier-journal.com/press-release/story/258355/theydo-shows-how-fedex-pfizer-and-kimberly-clark-turn-insight-into-results/
The article highlights how companies like FedEx, Pfizer, and Kimberly-Clark are leveraging customer insights to improve business outcomes. Examples include FedEx reducing credit notes by 20%, Pfizer shortening its insight-to-action cycle to less than two weeks, and Kimberly-Clark linking customer sentiment to sales. TheyDo's Beyond the Map 2026 event showcased these strategies, emphasizing the need for data-driven decision-making and accountability in customer experience.

AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma

https://seekingalpha.com/news/4674531-abbvie-inks-up-to-254b-bispecific-cancer-drug-deal-with-disco-pharma
AbbVie has announced a collaboration with DISCO Pharmaceuticals, involving an upfront payment and potential milestone payments totaling up to $2.54 billion. This deal aims to develop new bispecific cancer treatments, expanding AbbVie's early-stage pipeline in this therapeutic area.
Advertisement

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://live.euronext.com/en/financial-news/abbvie-expands-bispecific-cancer-med-push-25-billion-deal-germanys-disco
AbbVie has entered into an agreement with Germany's Disco Pharmaceuticals, committing up to $2.54 billion to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, along with tiered royalties, for its AND-gated bispecific therapeutics. This early-stage collaboration focuses on developing treatments that target cancer cells only when two specific proteins are present simultaneously, aiming to minimize harm to healthy tissue.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://www.reuters.com/legal/transactional/abbvie-expands-bispecific-cancer-med-push-with-up-25-billion-deal-with-germanys-2026-11-19/
AbbVie has agreed to a deal with Germany's Disco Pharmaceuticals worth up to $2.54 billion to develop next-generation bispecific cancer therapies. This collaboration focuses on "AND-gated" bispecific therapeutics for solid tumors, designed to target cancer cells more precisely by requiring the simultaneous presence of two target proteins. Disco will handle research and discovery, with AbbVie having exclusive licensing rights for further development.

Pfizer inks $2.3 B CAR-T deal with China's Starna Therapeutics

https://www.biospectrumasia.com/news/25/28704/pfizer-inks-2-3-b-car-t-deal-with-chinas-starna-therapeutics-.html
Pfizer has signed an exclusive licensing agreement worth up to $2.3 billion with China-based Starna Therapeutics to develop, manufacture, and commercialize three pre-IND in vivo CAR-T programs for autoimmune diseases outside Greater China. The deal includes an upfront payment of $330 million to Starna, with additional milestone payments and royalties. This collaboration expands Pfizer's Inflammation & Immunology pipeline, leveraging its RNA delivery and immunology expertise for next-generation cell therapy.

Adagene doses first patient in phase 1 trial of ADG138

https://www.investing.com/news/company-news/adagene-doses-first-patient-in-phase-1-trial-of-adg138-93CH-5038605
Adagene Inc. (NASDAQ:ADAG) has announced that the first patient has been dosed in a phase 1 study for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The study will assess the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors, with an aim to determine the recommended phase 2 dose. Preclinical data for ADG138 demonstrated reduced cytokine release, a longer half-life, and tumor regression in various HER2 tumor models.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco

https://kfgo.com/2026/11/19/abbvie-expands-bispecific-cancer-med-push-with-up-to-2-5-billion-deal-with-germanys-disco/
AbbVie has agreed to a deal worth up to $2.54 billion with Germany's Disco Pharmaceuticals to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, plus royalties, for its AND-gated bispecific therapeutics. This early-stage partnership aims to create treatments that specifically target cancer cells by requiring two proteins to be present simultaneously, thereby potentially reducing harm to healthy tissue.
Advertisement

Should Vaccine Medium Launch Require Action From Thermo Fisher Scientific (TMO) Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-vaccine-medium-launch-require-action-from-thermo-fish
Thermo Fisher Scientific recently launched Gibco VaxEvo CD 293 Medium, a new solution for adenovirus vaccine production. While this product supports the company's focus on pharma and biotech customers and bioproduction, analysts view it as an incremental development rather than a major factor for near-term results. The company's investment narrative continues to depend on the recovery of funding-sensitive customers and effective portfolio reshaping, alongside its consistent dividend payouts and strategic M&A activities.

Study shows GLP-1s may work in children as young as 6. Should kids be using them?

https://www.goodmorningamerica.com/news/story/clinical-trial-shows-glp-1s-effective-children-young-138245257
New research indicates that the weight loss medication Wegovy, with active ingredient semaglutide, may be effective for children with obesity as young as 6 years old, reducing BMI by 10% or more in a phase 3 clinical trial. While currently approved for ages 12 and up, Novo Nordisk plans to seek FDA approval to lower the age, sparking mixed reactions among doctors due to potential benefits in preventing severe obesity complications versus concerns about side effects like significant gastrointestinal issues and a reported decrease in linear growth. Physicians largely agree obesity needs addressing but debate the role of GLP-1s as a primary or supplementary tool for very young children.

Amgen Inc Stock (AMGN) Moved Down by 3.21% on Nov 18: What Signal Does It Send?

https://www.tradingkey.com/news/market-movers/262311625-market-movers-amgn-20261118
Amgen Inc. (AMGN) shares fell by 3.21% due to institutional caution regarding its clinical pipeline and challenges from patent cliffs and regulatory pricing pressures. Investors are closely watching the competitive dynamics of its investigational asset, MariTide, and the impact of the Inflation Reduction Act. Technical indicators show a neutral MACD and RSI, with an oversold Williams %R, while analysts maintain an average "Hold" rating with an average price target of $422.26.

C4 Therapeutics' Andrew Hirsch bets a microgram-dose degrader can beat CAR-T durability in myeloma

https://finance.biggo.com/news/b119e7f1f23ed123
C4 Therapeutics CEO Andrew Hirsch believes protein degradation, using the cell's own recycling system, can target "undruggable" proteins. Their lead asset, cemsidomide, a highly selective molecular glue, is in a pivotal-intent trial for myeloma, dosed at just 100 micrograms. Hirsch aims to combine cemsidomide with Pfizer's elranatamab to achieve CAR-T-level durability by countering T-cell exhaustion, with combination data expected in mid-2027 and a potential filing by end-2028.

Merck & Co Inc Stock (MRK) Moved Down by 3.35% on Nov 18: Facts Behind the Movement

https://www.tradingkey.com/news/market-movers/262311572-market-movers-mrk-20261118
Merck & Co Inc (MRK) stock declined by 3.35% due to operational challenges, sector rotation, and investor concerns over Keytruda's revenue concentration and impending patent cliff. The company also faces issues with its Gardasil vaccine franchise and risks from an aggressive M&A strategy. Despite a strong balance sheet, market participants are looking for proof of pipeline replacement power and stable organic growth beyond its primary assets.
Advertisement

Pfizer Pays $330 Million Upfront for Starna's In Vivo CAR-T Programs in $2.6 Billion Deal

https://finance.biggo.com/news/da621f80-59ef-40e7-ba51-06eb5c3a432b
Pfizer has agreed to an exclusive licensing deal with Starna Therapeutics, paying $330 million upfront for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. The total deal value could reach $2.63 billion including milestones and royalties, giving Pfizer rights outside Greater China and an option for China rights, as well as access to Starna's technology for oncology and a separate research collaboration. This move places Pfizer in the emerging in vivo cell therapy field, which has seen increased dealmaking from other large drugmakers like Eli Lilly.

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

https://www.biopharmadive.com/news/pfizer-starna-in-vivo-cell-therapy-autoimmune-disease-deal/875018/
Pfizer has entered a significant collaboration with Starna Therapeutics, paying $330 million upfront and up to $2.3 billion in milestone payments, to develop "in vivo" cell therapies for autoimmune diseases. This deal marks Pfizer's entry into the competitive "in vivo" CAR-T research space, aiming to reprogram cells inside the body and potentially simplify current "ex vivo" CAR-T processes that require cell harvesting and modification outside the body. The partnership leverages Pfizer's RNA-based medicine expertise and highlights a growing trend among drugmakers to pursue "in vivo" therapies for conditions beyond cancer, including lupus and multiple sclerosis.

CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s

https://www.biospace.com/drug-development/ctad-2026-biogen-aribio-lead-the-way-in-slowing-cognitive-decline-in-alzheimers
At the 2026 Clinical Trials on Alzheimer’s Disease conference, Biogen and AriBio reported positive results for their Alzheimer's therapies. Biogen's anti-tau therapy, diranersen, showed a 38% slowing of clinical decline over two years, supporting its advancement to Phase 3. AriBio's PDE5 inhibitor, AR1001, achieved success in a Phase 3 trial by slowing clinical decline by 31% in a monotherapy subgroup, with plans to discuss results with the FDA.

Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases

https://www.benzinga.com/markets/biotech/26/11/63393613/pfizer-strikes-multibillion-dollar-deal-to-take-on-autoimmune-diseases
Pfizer announced an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion to expand its inflammation and immunology pipeline and strengthen its presence in next-generation cell therapies. This deal grants Pfizer exclusive rights outside Greater China to develop, manufacture, and commercialize three early-stage CAR-T cell therapy programs targeting autoimmune diseases. The partnership leverages Starna's in vivo CAR-T technology and Pfizer's expertise in RNA-based medicines to address unmet needs in autoimmune disease treatment.

Pfizer Licenses In Vivo CAR T Therapies From Starna Therapeutics in $2.6B Deal

https://www.genomeweb.com/business-news/deals/gnw-pfizer-starna-licensing-cell-therapy-20261118/
Pfizer has entered into a licensing agreement with Starna Therapeutics for in vivo CAR T therapies, a deal potentially worth $2.6 billion. The specific details of the agreement highlight Pfizer's continued investment in advanced therapeutic technologies. This collaboration aims to advance the development of innovative treatments in the CAR T therapy space.
Advertisement

GLP-1s could be effective in children as young as 6. Should kids be using them?

https://abcnews.com/Health/clinical-trial-shows-glp-1s-effective-children-young/story?id=138245257
New research indicates that the weight loss medication Wegovy, containing semaglutide, significantly reduced BMI in children aged 6-11, with nearly 40% no longer having obesity after 68 weeks. While doctors acknowledge the potential benefits of early intervention for childhood obesity, concerns remain about side effects like severe gastrointestinal issues and potential impacts on linear growth in young children. Experts suggest GLP-1s could be a valuable tool for severe obesity when lifestyle changes are insufficient, but not as a first-line treatment.

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

https://www.streetinsider.com/Business+Wire/Thermo+Fisher+Scientific+Launches+Gibco%E2%84%A2+VaxEvo%E2%84%A2+CD+293+Medium+to+Advance+Adenovirus+Vaccine+Production/27367292.html
Thermo Fisher Scientific has launched Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined and animal origin-free cell culture medium. This product is designed to enhance suspension HEK293 cell growth and high-titer adenovirus production, crucial for vaccine development and manufacturing. It aims to simplify upstream workflows and improve productivity for human and animal health vaccine developers.

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal

https://www.reuters.com/legal/litigation/pfizer-licenses-car-t-therapies-chinas-starna-up-26-billion-deal-2026-11-18/
Pfizer has entered into an exclusive licensing agreement with China's Starna Therapeutics, worth up to $2.6 billion, to develop three CAR-T therapies for autoimmune diseases. This deal includes an upfront payment of $330 million to Starna, with additional payments contingent on development, regulatory, and sales milestones. The collaboration focuses on early-stage in vivo CAR-T therapies, which reprogram immune cells directly inside the body, contrasting with traditional CAR-T treatments that require external cell re-engineering.

Pfizer licenses in vivo CAR-T programs from Starna for $330M

https://ca.investing.com/news/stock-market-news/pfizer-licenses-in-vivo-cart-programs-from-starna-for-330m-93CH-4966525
Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo chimeric antigen receptor T-cell programs focused on autoimmune diseases. Under the agreement, Pfizer will pay Starna an upfront fee of $330 million and up to $2.3 billion in milestone payments, along with royalties on net sales. This deal expands Pfizer's Inflammation & Immunology pipeline and leverages its RNA delivery expertise for cell therapy approaches.

Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD

https://www.stocktitan.net/news/NBP/visara-announces-first-patient-dosed-in-ascend-phase-2b-trial-of-vis-lwrcrnsfm22n.html
Visara, a subsidiary of NovaBridge Biosciences (NBP), has dosed the first patient in its Phase 2b ASCEND trial for VIS-101 in wet AMD. The trial aims to evaluate the efficacy, safety, and durability of VIS-101, specifically its potential to extend treatment intervals up to seven months after three initial monthly doses. This study builds on Phase 2a results where approximately 50% of previously untreated patients in the 6 mg group remained retreatment-free for six months.
Advertisement

Nuvation Bio's David Hung: 90% Response Rate in ROS1 Lung Cancer Backs a China-Sourced Drug Strategy

https://finance.biggo.com/news/b50d19af799a7059
David Hung, CEO of Nuvation Bio, discusses the success of obetrosi, a ROS1 lung cancer drug acquired through AnHeart Therapeutics, which boasts a 90% first-line response rate and a median duration of response exceeding four years. Hung emphasizes the drug's efficacy and tolerability, particularly for a younger patient demographic often presenting with brain metastases. Nuvation Bio plans to expand its pipeline through further acquisitions from Chinese labs and academic centers and is developing obetrosi for adjuvant use.

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)

https://finance.yahoo.com/healthcare/articles/nanoviricides-inc-filed-quarterly-report-134500597.html
NanoViricides, Inc. has announced the filing of its Quarterly Report, highlighting that its broad-spectrum antiviral drug, NV-387 Oral Gummies, has entered two Phase II clinical trials. One trial is for the treatment of Ebola Bundibugyo Virus Disease, for which there is currently no licensed drug or vaccine, and the other is for Mpox (Monkeypox). The company also reported significant progress in its Measles drug program, receiving Orphan Drug and Rare Pediatric Disease Drug designations for NV-387, and detailed its financial position and future funding needs for advancing its clinical development pipeline.

Vaxcyte at jefferies global healthcare conference: adult vaccine path sharpens

https://www.investing.com/news/transcripts/vaxcyte-at-jefferies-global-healthcare-conference-adult-vaccine-path-sharpens-93CH-5035224
Vaxcyte provided updates on its pneumococcal vaccine franchise at the Jefferies Global Healthcare Conference, highlighting positive Phase III adult study data for VAX-31 which met all endpoints and demonstrated non-inferiority to existing vaccines while offering broader coverage. The company aims for a biologics license application filing in the first half of 2028 and anticipates Phase II infant program data in the first half of 2027. Vaxcyte sees a substantial commercial opportunity in the adult market, which is expected to grow significantly, driven by broader serotype coverage.

Olema Oncology Announces Preclinical Data Show Potent Oral KAT6A Degraders Inhibit ER+/HER2- Breast Cancer Growth

https://www.quiverquant.com/news/Olema+Oncology+Announces+Preclinical+Data+Show+Potent+Oral+KAT6A+Degraders+Inhibit+ER%2B%2FHER2-+Breast+Cancer+Growth
Olema Oncology reported promising preclinical data on its selective KAT6A degraders, showing strong antitumor activity and good tolerability in ER+/HER2- breast cancer models. These oral compounds demonstrated potent antiproliferative effects in both ESR1-mutant and wild-type models, leading to significant tumor growth inhibition and regression. The findings suggest KAT6A degradation could be a valuable new therapeutic strategy for breast cancer, complementing Olema's existing KAT6 inhibitor.

Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

https://seekingalpha.com/news/4674093-pfizer-inks-cell-therapy-licensing-deal-worth-up-to-26b
Pfizer has announced an exclusive licensing agreement with China-based Starna Therapeutics to develop and commercialize CAR-T therapies. The deal is valued at up to $2.6 billion. This collaboration aims to advance chimeric antigen receptor T-cell therapies.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement